Noopept (Omberacetam) Capsules
30 mg of N-phenylacetyl-L-prolylglycine ethyl ester, a dipeptide-derived small molecule, per hard gelatin capsule with cellulose filler. Every lot is tested in the manufacturer’s own laboratory, with a certificate.
| Compound | Noopept (Omberacetam; N-phenylacetyl-L-prolylglycine ethyl ester (GVS-111)) |
|---|---|
| CAS number | 157115-85-0 |
| Molecular formula | C17H22N2O4 |
| Contents | Noopept: 30 mg per capsule |
| Form | Hard gelatin capsules containing the active substance blended with microcrystalline cellulose, packed in a sealed bottle |
| Storage, sealed | Store at room temperature (15–25 °C) in the tightly closed original container, dry and protected from light |
| Format | Capsules in a sealed bottle |
Sizes and lots
- 30 mg per capsule · 1 bottle — $20.99
- 30 mg per capsule · Kit of 10 — $186.60
Noopept is the trade name of omberacetam, N-phenylacetyl-L-prolylglycine ethyl ester, also coded GVS-111: a small molecule built on the dipeptide prolylglycine, with the amino end capped by a phenylacetyl group and the carboxyl end closed as an ethyl ester. This listing supplies it in hard gelatin capsules, 30 mg per capsule. Research on it, almost all from one Moscow group, has measured neurotrophin gene expression in the rat brain and outcomes in a rat stroke model.
What is in each capsule
Each hard gelatin capsule holds 30 mg of omberacetam blended with microcrystalline cellulose, which makes up the balance of the fill. The safety data sheet gives omberacetam as a nominal 7.5% w/w of the capsule contents, with gelatin as the shell. The active is listed under CAS 157115-85-0 with the formula C17H22N2O4, and none of the three components is classified as hazardous.
The capsules are packed in a sealed bottle. Store them at room temperature, 15 to 25 °C, in the tightly closed original container, dry and protected from light. Unlike the freeze-dried peptides elsewhere in the catalogue, they need neither a freezer nor a refrigerator. Every component is listed on the safety data sheet linked in the specifications above.
Peptide, racetam or neither
Omberacetam sits awkwardly between categories. Its developers call it a dipeptide, and a proline-containing one1,2: it has two amino acid residues, L-proline joined to glycine. But neither end of the chain is free. A phenylacetyl group caps the proline nitrogen and the glycine is an ethyl ester, so the compound has none of the charged termini of an ordinary peptide and behaves more like a small drug molecule than like the peptides sold in vials.
The racetam label is just as loose. The Moscow group designed the molecule by rebuilding the active arrangement of piracetam out of amino acids, and the World Health Organization gave it the nonproprietary name omberacetam in 2018. Chemically it has no 2-oxo-pyrrolidine ring, the defining feature of piracetam, so the -racetam stem describes a pharmacological family, not a structural one. How the design came about is told in the Noopept (omberacetam) guide.
What the research covers
Where the compound came from
Omberacetam came out of work that synthesised a series of N-acylprolyl-containing dipeptides and screened them for antiamnesic activity in animals3. The group, based at the Zakusov Institute of Pharmacology in Moscow, published most of what followed.
Rat studies
In a rat model of photochemical stroke, in which a light-activated dye causes a local clot in the frontal cortex, GVS-111 given after the lesion lessened the resulting deficit in passive avoidance and reduced the volume of the infarct2. The authors attributed the neuroprotection to antioxidant activity, reduced glutamate toxicity and block of voltage-gated ion channels2. A later Northern blot study measured NGF and BDNF mRNA in rat cortex and hippocampus after a single exposure and after long-term exposure1. In the hippocampus, mRNA for both neurotrophins rose after a single exposure. In the cortex, expression fell below control after a single exposure, and long-term exposure brought only a slight rise in BDNF. Repeated exposure produced no tolerance and strengthened the hippocampal effect1.
What is not established
Frequently asked questions
What does each capsule contain?
30 mg of omberacetam (Noopept, GVS-111) blended with microcrystalline cellulose filler in a hard gelatin shell. The safety data sheet gives the active as a nominal 7.5% w/w of the capsule contents, and none of the components is classified as hazardous.
Is Noopept a peptide?
Only loosely. It is built from two amino acids, proline and glycine, but both ends are capped, one with a phenylacetyl group and one as an ethyl ester, so it behaves as a small molecule. Despite the name omberacetam, it is not chemically a racetam either.
How should the capsules be stored?
At room temperature, 15 to 25 °C, in the tightly closed original bottle, dry and protected from light. Unlike the freeze-dried peptides in the catalogue, the capsules need no refrigeration or freezing.
References
- Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. 2008;146(3):334-7. DOI · PubMed
- Ostrovskaya RU, Romanova GA, Barskov IV, et al. Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model. Behav Pharmacol. 1999;10(5):549-53. DOI · PubMed
- Gudasheva T, Voronina T, Ostrovskaya R, et al. Synthesis and antiamnesic activity of a series of N-acylprolyl-containing dipeptides. European Journal of Medicinal Chemistry. 1996;31(2):151-157. DOI
For laboratory research use only. Not for human or veterinary consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.